Ifosfamide

Generic Name
Ifosfamide
Brand Names
Ifex
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
3778-73-2
Unique Ingredient Identifier
UM20QQM95Y
Background

Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication

Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.

Associated Conditions
Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
Associated Therapies
-
Clinical Trials
Related News

Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma

Phase 2
Completed
Conditions
Soft Tissue Sarcoma
Interventions
Drug: Ifosfamide
First Posted Date
2010-04-13
Last Posted Date
2012-03-20
Lead Sponsor
Grupo Espanol de Investigacion en Sarcomas
Target Recruit Count
32
Registration Number
NCT01102608
Locations
🇪🇸

Grupo Espanol de Investigación en Sarcomas, Barcelona, España, Spain

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

First Posted Date
2010-04-01
Last Posted Date
2018-01-23
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
20
Registration Number
NCT01097057
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

First Posted Date
2010-01-25
Last Posted Date
2017-08-29
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
175
Registration Number
NCT01055314
Locations
🇺🇸

Seattle Children's Hospital, Seattle, Washington, United States

🇺🇸

Riley Hospital for Children, Indianapolis, Indiana, United States

🇺🇸

Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States

and more 136 locations

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

First Posted Date
2009-12-04
Last Posted Date
2022-04-28
Lead Sponsor
Children's Oncology Group
Target Recruit Count
166
Registration Number
NCT01026220
Locations
🇺🇸

Sinai Hospital of Baltimore, Baltimore, Maryland, United States

🇺🇸

Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

🇺🇸

Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States

and more 174 locations

Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

Phase 2
Conditions
Lymphoma
First Posted Date
2009-09-10
Last Posted Date
2013-08-26
Lead Sponsor
Cancer Research UK
Target Recruit Count
150
Registration Number
NCT00974792
Locations
🇬🇧

Nottingham City Hospital, Nottingham, England, United Kingdom

Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer

Phase 2
Terminated
Conditions
Pancreatic Cancer
First Posted Date
2009-08-27
Last Posted Date
2012-02-01
Lead Sponsor
IRCCS San Raffaele
Target Recruit Count
21
Registration Number
NCT00967291
Locations
🇮🇹

Istituto Scientifico H. San Raffaele, Milan, Italy

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

First Posted Date
2009-08-27
Last Posted Date
2020-04-20
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
20
Registration Number
NCT00967369
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

First Posted Date
2009-08-17
Last Posted Date
2018-08-27
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
4
Registration Number
NCT00960063

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

First Posted Date
2009-08-07
Last Posted Date
2021-09-30
Lead Sponsor
GOG Foundation
Target Recruit Count
637
Registration Number
NCT00954174
Locations
🇺🇸

Sinai Hospital of Baltimore, Baltimore, Maryland, United States

🇺🇸

Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States

🇺🇸

University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States

and more 532 locations

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

First Posted Date
2009-07-10
Last Posted Date
2024-08-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
64
Registration Number
NCT00936936
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Fred Hutchinson Cancer Center, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy